Here's how NATURE.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NATURE . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Nature.com Make Money
  6. How Much Does Nature.com Make
  7. Keywords
  8. Topics
  9. Schema
  10. Social Networks
  11. External Links
  12. Analytics And Tracking
  13. Libraries
  14. Hosting Providers

We are analyzing https://www.nature.com/articles/481275a.

Title:
Reprogramming clinical outcome | Nature
Description:
Most breast tumours express the oestrogen receptor-α (ER), and this transcription factor is seen as an important drug target for the treatment of breast cancer. Jason Carroll and colleagues have mapped ER binding sites in solid primary cancers for the first time, and find distinct ER-binding profiles that are mediated in part by the FoxA1 DNA-binding protein and are associated with better or worse clinical outcome. As well as providing a potentially useful method of prognosis, this work may help to answer one of the major questions in breast cancer biology: how some ER+ tumours become drug resistant.
Website Age:
30 years and 10 months (reg. 1994-08-11).

Matching Content Categories {📚}

  • Education
  • Animals & Wildlife
  • Social Networks

Content Management System {📝}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of nature.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {💸}


Display Ads {🎯}


The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.

Ads are managed by yourbow.com. Particular relationships are as follows:

Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.com

Reseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.com

How Much Does Nature.com Make? {💰}


Display Ads {🎯}

$63,100 per month
According to our algorithms, Nature.com's monthly online income from display advertising ranges from $42,042 to $115,616.

Keywords {🔍}

nature, article, google, scholar, cas, cancer, access, content, cookies, privacy, deblois, giguère, data, clinical, outcome, vincent, carroll, research, advertising, information, subscribe, january, geneviève, genes, breast, institution, buy, cell, author, permissions, optional, media, personal, parties, policy, journals, log, journal, news, views, published, reprogramming, cite, binding, letter, options, print, online, issue, learn,

Topics {✒️}

nature portfolio permissions reprints privacy policy advertising nature genet nature rev geneviève deblois & vincent giguère social media nature 481 nature author correspondence reprogramming clinical outcome oestrogen-receptor protein modulates personal data springerlink instant access data protection permissions breast cancer caryn privacy article deblois ross-innesrory starkjason explore content subscription content european economic area clinical outcome institutional subscriptions read quebec h3a 1a3 accepting optional cookies vincent giguère journals search log ross-innes manage preferences breast cancer access issue learn content article purchase article cite cancer res optional cookies choices https essential cookies cookies skip cancer cell 20 journal publish institution buy institution subscribe usage analysis varying standards

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Reprogramming clinical outcome
         description:On binding to its target hormone, the oestrogen-receptor protein modulates the expression of many genes. Changes in the receptor's interaction with DNA have now been linked to clinical outcome in patients with breast cancer. See Letter p.389 Most breast tumours express the oestrogen receptor-α (ER), and this transcription factor is seen as an important drug target for the treatment of breast cancer. Jason Carroll and colleagues have mapped ER binding sites in solid primary cancers for the first time, and find distinct ER-binding profiles that are mediated in part by the FoxA1 DNA-binding protein and are associated with better or worse clinical outcome. As well as providing a potentially useful method of prognosis, this work may help to answer one of the major questions in breast cancer biology: how some ER+ tumours become drug resistant.
         datePublished:2012-01-18T00:00:00Z
         dateModified:2012-01-18T00:00:00Z
         pageStart:275
         pageEnd:276
         sameAs:https://doi.org/10.1038/481275a
         keywords:
            Breast cancer
            Cancer genetics
            Science
            Humanities and Social Sciences
            multidisciplinary
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2F481275a/MediaObjects/41586_2012_Article_BF481275a_Fig1_HTML.jpg
         isPartOf:
            name:Nature
            issn:
               1476-4687
               0028-0836
            volumeNumber:481
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Geneviève Deblois
               affiliation:
                     name:Medicine and Oncology, McGill University, Montreal, Quebec H3A 1A3, Canada.
                     address:
                        name:Geneviève Deblois and Vincent Giguère are at the Goodman Cancer Research Centre and Departments of Biochemistry, Medicine and Oncology, McGill University, Montreal, Quebec H3A 1A3, Canada.,
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Vincent Giguère
               affiliation:
                     name:Medicine and Oncology, McGill University, Montreal, Quebec H3A 1A3, Canada.
                     address:
                        name:Geneviève Deblois and Vincent Giguère are at the Goodman Cancer Research Centre and Departments of Biochemistry, Medicine and Oncology, McGill University, Montreal, Quebec H3A 1A3, Canada.,
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:NewsArticle
      context:https://schema.org
NewsArticle:
      headline:Reprogramming clinical outcome
      description:On binding to its target hormone, the oestrogen-receptor protein modulates the expression of many genes. Changes in the receptor's interaction with DNA have now been linked to clinical outcome in patients with breast cancer. See Letter p.389 Most breast tumours express the oestrogen receptor-α (ER), and this transcription factor is seen as an important drug target for the treatment of breast cancer. Jason Carroll and colleagues have mapped ER binding sites in solid primary cancers for the first time, and find distinct ER-binding profiles that are mediated in part by the FoxA1 DNA-binding protein and are associated with better or worse clinical outcome. As well as providing a potentially useful method of prognosis, this work may help to answer one of the major questions in breast cancer biology: how some ER+ tumours become drug resistant.
      datePublished:2012-01-18T00:00:00Z
      dateModified:2012-01-18T00:00:00Z
      pageStart:275
      pageEnd:276
      sameAs:https://doi.org/10.1038/481275a
      keywords:
         Breast cancer
         Cancer genetics
         Science
         Humanities and Social Sciences
         multidisciplinary
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2F481275a/MediaObjects/41586_2012_Article_BF481275a_Fig1_HTML.jpg
      isPartOf:
         name:Nature
         issn:
            1476-4687
            0028-0836
         volumeNumber:481
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Geneviève Deblois
            affiliation:
                  name:Medicine and Oncology, McGill University, Montreal, Quebec H3A 1A3, Canada.
                  address:
                     name:Geneviève Deblois and Vincent Giguère are at the Goodman Cancer Research Centre and Departments of Biochemistry, Medicine and Oncology, McGill University, Montreal, Quebec H3A 1A3, Canada.,
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Vincent Giguère
            affiliation:
                  name:Medicine and Oncology, McGill University, Montreal, Quebec H3A 1A3, Canada.
                  address:
                     name:Geneviève Deblois and Vincent Giguère are at the Goodman Cancer Research Centre and Departments of Biochemistry, Medicine and Oncology, McGill University, Montreal, Quebec H3A 1A3, Canada.,
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Nature
      issn:
         1476-4687
         0028-0836
      volumeNumber:481
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Medicine and Oncology, McGill University, Montreal, Quebec H3A 1A3, Canada.
      address:
         name:Geneviève Deblois and Vincent Giguère are at the Goodman Cancer Research Centre and Departments of Biochemistry, Medicine and Oncology, McGill University, Montreal, Quebec H3A 1A3, Canada.,
         type:PostalAddress
      name:Medicine and Oncology, McGill University, Montreal, Quebec H3A 1A3, Canada.
      address:
         name:Geneviève Deblois and Vincent Giguère are at the Goodman Cancer Research Centre and Departments of Biochemistry, Medicine and Oncology, McGill University, Montreal, Quebec H3A 1A3, Canada.,
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Geneviève Deblois
      affiliation:
            name:Medicine and Oncology, McGill University, Montreal, Quebec H3A 1A3, Canada.
            address:
               name:Geneviève Deblois and Vincent Giguère are at the Goodman Cancer Research Centre and Departments of Biochemistry, Medicine and Oncology, McGill University, Montreal, Quebec H3A 1A3, Canada.,
               type:PostalAddress
            type:Organization
      name:Vincent Giguère
      affiliation:
            name:Medicine and Oncology, McGill University, Montreal, Quebec H3A 1A3, Canada.
            address:
               name:Geneviève Deblois and Vincent Giguère are at the Goodman Cancer Research Centre and Departments of Biochemistry, Medicine and Oncology, McGill University, Montreal, Quebec H3A 1A3, Canada.,
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Geneviève Deblois and Vincent Giguère are at the Goodman Cancer Research Centre and Departments of Biochemistry, Medicine and Oncology, McGill University, Montreal, Quebec H3A 1A3, Canada.,
      name:Geneviève Deblois and Vincent Giguère are at the Goodman Cancer Research Centre and Departments of Biochemistry, Medicine and Oncology, McGill University, Montreal, Quebec H3A 1A3, Canada.,
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(38)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Prism.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mxa-002c5801.gslb.pphosted.com
  • mxb-002c5801.gslb.pphosted.com

Name Servers:

  • pdns1.ultradns.net
  • pdns2.ultradns.net
  • pdns3.ultradns.org
  • pdns4.ultradns.org
  • pdns5.ultradns.info
  • pdns6.ultradns.co.uk
4.17s.